Singapore
Worked on improving the efficacy and safety of antigen-specific immunotherapy for Acute Myeloid Leukemia (AML), including Chimeric Antigen Receptor (CAR)-based therapy at Roland Walter's lab Publications: Lim, S.Y.T., Cole, F.M., Laszlo, G.S. et. al. Targeting the membrane-proximal domain of CD33 to maximize the efficacy of natural killer cell-based immunotherapies. Haematologica. 110(5):1197-1201. (2025). https://doi.org/10.3324/haematol.2024.286593. Lim, SY.T., Huo, J., Laszlo, G.S. et al. Optimizing Siglec-8-Directed Immunotherapy for Eosinophilic and Mast Cell Disorders. Cancers (Basel). 16(20):3476. (2024). https://doi.org/10.3390/cancers16203476. Fiorenza, S., Lim, S.Y.T., Laszlo, G.S. et al. Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy. Mol Ther Oncol.32(3):200854. (2024). https://doi.org/10.1016/j.omton.2024.200854.
DPhil student in Mark Howarth's group in the Department of Biochemistry Co-developed the NeissLock and split-NeissLock protein crosslinking systems for new modes of therapeutic delivery (UK patents: 2003683.6, 2504781.2) Publications: Scheu, A.H.A.*, Lim, S.Y.T.*, Metzner, F.J. et al. NeissLock provides an inducible protein anhydride for covalent targeting of endogenous proteins. Nat Commun 12, 717 (2021). https://doi.org/10.1038/s41467-021-20963-5 Lim, S.Y.T.*, Keeble, A.H.*, Howarth, M.R. Split NeissLock with Spy-Acceleration Arms Mammalian Proteins for Anhydride-Mediated Cell Ligation. ACS Chem Biol. (2025). https://doi.org/10.1021/acschembio.5c00515
Involved in conceptualization of business model for biotech start-up involved in discovery of multispecific antibodies (Patent: WO2022200804A2) Won 2nd prize in Panacea Stars Develop 2020 and participated in YCombinator Winter Batch 2021
Generated stable cell lines for phenotypic screening of libraries for leads that can reactivate mutant p53 Investigated rescue of p53 function using single-chain variable fragments (ScFvs) and other specific peptides